INTRODUCTION
Diabetic glomerulopathy is the most serious complication of insulin-dependent diabetes. Nephropathy eventually develops in 3040% of diabetic patients and is responsible for tenfold increases in cardiovascular mortality due to end-stage renal failure and hypertension [l, 21. Although the mechanisms responsible for the development of diabetic nephropathy are ill-defined, glomerulosclerosis is preceded by a stage of renal hyperfiltration and hypertrophy [3, 41 . In streptozotocin-diabetic rats, glomerulosclerosis developed despite adequate glycaemic control, supporting a predominancy of renal haemodynamic alterations over metabolic control in the development of glomerulopathy [5-71. More recently, Yoshida et al. [S] , using a nondiabetic remnant kidney model, demonstrated that renal hypertrophy can induce glomerulosclerosis without concomitant glomerular hypertension. A role for growth factors in the induction of renal hypertrophy and glomerulosclerosis was also shown in studies using transgenic mice [9] . These animals expressing exaggerated levels of either insulingrowth factor 1 (IGF-1) or growth hormone (GH), displayed glomerular and renal hypertrophy. In addition, transgenic mice expressing elevated levels of GH, but not of IGF-1, de morphological lesions typical of diabetic glo clerosis despite the absence of hypertension and hyperglycaemia. In diabetic patients characterized by poor metabolic control, increases in plasma GH concentration have been reported [lo, 111, suggesting a stimulatory role of GH or its primary effector, IGF-1, in hypertrophic processes within the kidney and other vascular beds [lo] .
Octreotide, a somatostatin analogue, is a potent suppressor of GH secretion and has provided successful therapy in diseases characterized by excessive GH release, such as acromegaly. In acute studies examining diabetic rats, octreotide reduced diabetic hyperfiltration, apparently by a t effect on vascular smooth muscle [12, 131. ional shortterm studies showed that octreotide reduced and even prevented initial renal hypertrophy in streptozotocin-treated rats [14, 151 . Recently, Serri et al. [16] administered octreotide as a continuous subcutaneous infusion to humans with insulindependent diabetes for a period of 12 weeks. Compared with control diabetic patients, patients treated with octreotide exhibited significant reductions in glomerular filtration and mean total kidney volume at the end of the trial period.
Although these findings are encouraging, none has examined the preventative role of octreotide in the progression of diabetic glomerulosclerosis. We therefore assessed the effects of chronic octreotide therapy on the prevention of renal hypertrophy and hyperfiltration and on the evolution of urinary protein excretion and glomerular pathology in rats made diabetic using streptozotocin. We attempted to accelerate the progression of glomerular injury and nephron loss by using the uninephrectomized diabetic rat model developed by O'Donnell et al.
~171.

METHODS
We purchased 40 male Sprague-Dawley rats, aged 8 weeks, from Iffa Credo (L'Arbresle, France). The animals were housed in groups of three in a temperature-controlled colony room equipped with a 12 h light/l2 h dark cycle. Throughout the experiment, the animals were given continuous access to tap water and a standarized rat pellet diet containing 25% (w/v) protein.
After 1 week of habituation, all rats were subjected to right nephrectomy under ether anaesthesia. After 3 days of recovery, the rats were randomly divided into four groups (n= 10): a control group receiving daily injections of placebo, an octreotide group receiving daily subcutaneous injections of 20 pg of octreotide (Sandostatin; Sandoz, Basel, Switzerland), a diabetic group given a single intravenous injection of streptozotocin (60 mg/kg) in citrate buffer under light ether anaesthesia, followed by daily evening injections of a heat-treated ultralente insulin (Novo Industries, Copenhagen, Denmark), and a diabetic group treated with octreotide. Daily insulin doses were adjusted to maintain the blood glucose concentration between 200 and 400 mg/dl. These injections averaged approximately 2 units/ day. The first octreotide injection of 20pg was given 1 h after streptozotocin administration, and octreotide was injected thereafter as two daily injections of 1Opg each.
During the development stage of the experiment, lasting approximately 4 months, several parameters were regularly examined including blood glucose concentration and urinary protein excretion. Blood glucose concentration was determined every 4 weeks in tail blood from conscious rats, placed on bandelettes (Boehringer, Mannheim, Germany) and quantified by photometry (Boehringer). Monthly metabolic cage measurements provided estimations of 24 h food and water intakes as well as urinary protein excretion (Biotrol Protein Kit; Biotrol, Paris, France).
At the completion of the developmental phase, all rats underwent haemodynamic studies. One hour before surgery, diabetic and non-diabetic rats assigned to octreotide treatment were administered a final 20pg injection of octreotide, whereas controls received placebo. All rats were anaesthetized with pentobarbital (50 mg/100 g body weight) and placed on a warming table regulated at 38°C. Polyethylene catheters (Clay Adams, Parsippany, NJ, U.S.A.) were inserted in the trachea, right jugular vein, right and left femoral arteries and in the urinary bladder. Saline solution (150mmol/l) was administered via the jugular catheter at a dose of 0.5% of body weight over 20min to replace plasma losses associated with anaesthesia and surgery. Infusion was continued using a solution of C3H]inulin (6.5pCi/ml), p-['4C]amin~hippurate ([14C]PAH) (0.6 pCi/ml), pentobarbital (2.5 mg/ml) and saline given at a rate of 10plmin-1 100-'g body weight. After an equilibration period of 1 h, urine was collected from the bladder catheter during three 30 min periods. Blood was drawn continuously from the right femoral catheter using an infusion pump (model 351; Sage Instruments, Cambridge, MA, U.S.A.) at a rate of 13plmin-' 1OOg-1 body weight, to provide a total of 39Opl of blood for each period. Packed cell volume (PCV) was immediately recorded. Systolic blood pressure was recorded throughout the clearance periods via the left femoral catheter using a transducer (P23DB; GouldStatham, Inc. Cleveland, OH, U.S.A.) and an amplifier with a recorder (Gould Instruments, Ballainvilliers, France). Radioactivity was measured using a liquid scintillation counter (1212 Rackbeta; LKB Wallac, Turku, Finland).
Clearances of inulin (CI,,) and PAH (CPAH) were calculated by standard methods. Filtration fraction (FF) was calculated from Ci,,/CPAH, and renal vascular resistance (RVR) from the formula: RVR = MAP x (1 -PCV)/CPAH, where MAP is mean arterial blood pressure. At the end of the clearance studies, blood was collected from the descending aorta into tubes containing EDTA, centrifuged, and plasma samples were stored at -80°C for later analysis.
Plasma IGF-1 concentration was assayed after a modified acid ethanol extraction using a cyroprecipitation step [18] . R i a . was performed using rabbit anti-human IGF-1 antibody, UBK-487, obtained from NIPP (Baltimore, MD, U.S.A.), radiolabelled 1251-IGF-l (Amersham, Cardiff, U.K.), and recombinant IGF-1 as a standard (ARN 4140, Amersham). Separation of bound and free fractions was achieved with PR 1000, an immunoprecipitating reagent (iCIS, Gif-sur-Yvette, France). Crossreaction with rat IGF-1 was found to be more than 90%. All samples were measured at one time giving an intra-assay coefficient of variation of 7.5% at a concentration of 150 ng of IGF-l/ml.
Immediately after exsanguination, each kidney was removed, carefully cleaned, weighed, and two coronal slices 2-3mm thick were fixed in Dubosq Brasil fixative. Three-micrometre thick paraffin sections were then stained using Mason's trichrome with Light Green, periodic acid-Schiff and silver impregnation according to the methods of Jones, respectively, for examination by light microscopy. The sections were coded and analysed by a pathologist (L.-H.N.) in a double-blind manner. For each specimen, a mean of 100 glomeruli were examined from comparable portions of the kidney, midway between the two poles. A semi-quantitative system was used to grade glomerular and tubular pathology consistent with diabetic alterations. Mild interstitial lesions were defined by the presence of tubular dilatations and cysts. Severe tubular lesions were defined by the presence of focal fibrosis, inflammatory cells, tubular dilatation and/or intratubular casts. Glomerular lesions were characterized by mesangial expansion with focal and/or segmental glomerulosclerosis. The data are presented as means kSEM, and were analysed using appropriate single or repeated measures two-way analysis of variance [19] . Prevalance of pathological lesions in the different groups were examined using a contingency table (x2 test). Differences between groups were considered significant at the 0.05 level.
RESULTS
Long-term outcomes
The evolution of body weight, over 14 weeks of study, is illustrated in Fig. 1 . Although all rats gained weight during the course of the study (P < O.OOOl), diabetes suppressed normal growth, resulting in differences of 100 g between diabetic and control groups at the completion of the trial (P <O.OOOl) Independently of this effect, octreotide diminished growth rate equally in diabetic and nonAs shown in Fig. 2 , diabetic rats exhibited moderate hyperglycaemia during the entire study (P c 0.0001). Hyperglycaemia was relatively stable, except for a decline during week 6 of the study due to adjustments in insulin administration (P < 0.0001). That diabetes induced degenerative changes in renal function was indicated by progressive increases in urinary protein excretion in both diabetic groups (Fig. 3) . Elevated protein excretion was manifested during the second month of diabetes (P < 0.05), and increased exponentially thereafter.
Kidney weight, metabolic status and indications of extracellular fluid balance at the completion of the study are shown in Table 1 . Diabetes generated an expected increase in kidney size (P < O.OOOl), although no effect of octreotide was observed. Rats made diabetic also exhibited hyperphagia (P < 0.001) and polydipsia (P -= 0.001) compared with controls.
PCV was slightly reduced by diabetes (P < 0.05) and by octreotide treatment (P < 0.05). Similar findings were noted for plasma protein concentrations, although these alterations did not attain statistical significance. Induction of diabetes profoundly depressed serum IGF-1 levels (P <0.0001) with no effect of octreotide treatment.
Haemodynamic studies
Diabetic rats exhibited a pattern of renal haemodynamics characteristic of animals in moderate glycaemic control ( Table 2 ). The analysis of variance for systolic blood pressure in anaesthetized rats revealed a condition by treatment interaction (P c 0.05) reflecting higher blood pressures in octreotide-treated non-diabetic rats relative to their placebo-treated counterparts. Whole-kidney GFR was elevated in both diabetic groups in relation to control rats (Pc0.01). However, when GFR was normalized for kidney weight hyperfiltration in diabetic animals was abolished. In addition, the tendency for elevated GFR in the two octreotidetreated groups became significant when glomerular filtration was expressed as a function of kidney weight (P ~0 . 0 5 ) . Diabetic rats treated with octreotide and placebo exhibited modest elevations in renal plasma flow (P<O.O5). FF was also higher in diabetic groups (P<O.Ol) and RVR tended to be lower, although this difference was not significant.
Light microscopy
The main consistent pathological feature was a striking glomerular enlargement in diabetic rats, which was independent of treatment with octreotide or placebo (Figs. 4u-4~) . Renal pathological lesions were otherwise relatively scarce and totally absent in both of the diabetic groups. In kidneys with glomerular lesions, no more than 10% of glomerular were affected. For this reason, lesions were expressed not as incidence of glomerular lesions, but as incidence of kidneys demonstrating significant tubular or glomerular lesions (Table 3) . Tubular lesions were significantly more frequent in the diabetic groups (P c 0.01) than in the control groups, but no effect of octreotide was found in either the non-diabetic or diabetic groups. Glomerular lesions were significantly more frequent in diabetic groups than in non-diabetic groups (P<0.05) and in octreotide-treated groups than in their respective placebo-treated groups (P < 0.05) irrespective of diabetes status.
DISCUSSION
In agreement with earlier reports [3, 4, 71, insulin-dependent diabetic rats maintained under moderate glycaemic control were characterized by renal hypertrophy, glomerular hyperfiltration and subnormal body growth despite hyperphagia. The causes of hyperfiltration appeared to be multifactorial. Elevated glomerular filtration appeared to be related to reductions in RVR associated with increased renal plasma flow [7] . However, increased FF in diabetic rats suggested either an increase in glomerular pressure gradient or an increase in ultrafiltration coefficient [3, 171 through glomerular hypertrophy and presumably increased filtration surface area. The preponderant influence of renal hypertrophy on hyperfiltration was inferred in the current study since GFRs in diabetic rats were abolished when the parameter was normalized for kidney weight [3, 171. That serum IGF-1 levels are markedly reduced in streptozotocin-diabetic rats has been known for some time [20] . The reduced serum IGF-1 levels in our diabetic rats may explain, in part, the reduced growth rates of the two diabetic groups [21] . Octreotide was further reported to decrease renal tissue IGF-1 concentrations in the short term [14, 151. However, the relative contribution of tissue and circulating IGF-1 to bioactivity is not known. Renal tissue IGF-1 concentration increases rapidly with the onset of diabetes in rats and parallels the development of renal hypertrophy [ 14, 221. Paradoxically, renal IGF-1 messenger RNA, a marker of cellular gene expression for the hormone, is unaltered and even depressed in diabetic rats [20, 231. Although enhanced translation of messenger RNA cannot be excluded, the elevated tissue IGF-1 level may simply reflect enhanced uptake of plasma IGF-1 by the diabetic kidney.
Serum GH levels are increased in diabetic patients characterized by poor metabolic control, but are diminished in streptozotocin-diabetic rats [24] . However, when dwarf rats, which are genetically deficient in GH, were rendered diabetic by streptozotocin, renal hypertrophy was blunted despite a significant increase in the renal IGF-1 level [25] . These findings suggest that a synergistic interaction between circulating GH and IGF-1 has an effect on the full expression of renal hypertrophy in diabetes. Although it may have been valuable to characterize plasma GH in the current study, plasma levels of this hormone undulate widely in In contrast to their findings of significant mesangial matrix expansion and focal glomerulosclerosis, we noted only moderate increases in urinary protein excretion accompanied by occasional glomerular lesions. This disparity may be related to the level of glycaemia in the two studies. Diabetic rats in the study of ODonnell et al.
[17] suffered from severe glycaemia (565 mg/dl) contrasting with moderate control ( N 300 mg/dl) in the current study. Although food intakes were not mentioned in the latter study, diabetic rats with poor metabolic control may have consumed greater amounts of food resulting in greater protein intakes, an effect known to accelerate glomerulosclerosis [S]. A further difference was the introduction of diabetes before uninephrectomy in the study of O'Donnell et al. [17] , as opposed to the reverse order in the present experiment. However, the importance of this order effect on renal pathology is unknown.
The current study assessed the preventive influences of long-term administration of octreotide on the renal structural and haemodynamic alterations caused by diabetes. Somatostatin is a potent tor of the release of GH, insulin, glucagon and enterohormones C27-J. Octreotide, an analogue of somatostatin, displays an inhibitory potency 80-fold stronger than its endogenous counterpart. In addition, subcutaneous octreotide is characterized by a slower plasma clearance rate, and lacks GH rebound after subcutaneous administration [28] . In short-term studies of diabetes, pharmacological infusions of octreotide suppressed both renal plasma flow and glomerular filtration in streptozotocintreated rats [12, 131. Contrary to these findings, we found no influence of long-term octreotide treatment on renal haemodynamics. In fact, octreotide increased GFR when this parameter was normalized for kidney weight. Other acute studies demonstrated reduced renal hypertrophy with octreotide treatment [lS], and even prevention of initial kidney growth in early diabetes [14] . Our finding of equivalent kidney sizes in octreotide-and placebo-treated groups after 14 weeks of diabetes suggests that inhibition of renal hypertrophy by the drug may be less effective during a longer course of diab Since renal tissue lesions in our diabetic model were relatively scarce, it was difficult to establish a preventative effect of long-term octreotide treatment. Nevertheless, the degree of glomerular hypertrophy and the incidence of tubular dilatation and glomerular segmental lesions were at least similar in diabetic rats treated by octreotide or by placebo.
Only a single published study has described longer-term effects of octreotide in diabetes. Serri et al. [16] demonstrated that 12 weeks of subcutaneous octreotide administration reduced GFR and kidney volume in patients with insulin-dependent diabetes. In the light of these findings, the lack of salutary effects of octreotide in diabetic rats is puzzling. The ability of the drug to influence diabetic pathology may depend on several factors including dose, the presence of pre-existing diabetes and on differing responses to octreotide between humans and rats [7] . fact, the high doses in the present study produced an unexpected attenuation of body growth in both diabetic and non-diabetic octreotide-treated groups, a finding previously unreported in the literature on diabetes. Drug-induced sickness or inactivity cannot explain this result since food and water intakes were similar in octreotide and placebo-treated groups. Alternatively, the absence of effects of octreotide may be related to good metabolic control in diabetic rats in the current study. Indeed, strict insulin treatment abolishes increases in both kidney IGF-1 levels and renal hypertrophy.
Furthermore, the degree of kidney IGF-1 accumulation 2 days after streptozotocin administration was found to be directly proportional to blood glucose levels in rats with graded severities of diabetes [30]. The combination of diabetes and uninephrectomy induces additive increases in both kidney IGF-1 accumulation and renal enlargement [31] , suggesting that some of these hypertrophic stimuli could be unreponsive to octreotide.
In summary, long-term octreotide therapy did not prevent early pathological changes characteristic of insulin-dependent diabetes in rats. Although the current dose of octreotide was strong enough to inhibit normal body growth and reduce PCV, the drug did not inhibit diabetic renal hypertrophy, glomerular hyperfiltration, tissue damage or the development of elevated urinary protein excretion after 14 weeks of diabetes. The lack of effect of octreotide on several parameters suggests that the dose may not have been sufficient. Support for this possibility comes from the fact that octreotide suppressed serum IGF-1 levels in other studies [14, 16 , 291, whereas we observed no effect of the drug on serum IGF-1 levels. Insufficient administration of octreotide was unlikely, however, because octreotide-treated rats received a dose approximately ten times stronger than the highest dose used by Serri et al. [16] . In
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